TGFB1 and graft versus host disease: Given the higher expression of NKG2D after CT treatment in our syngeneic HSCT model, we could speculate that this regimen could also result in a stronger GvHD protection suggesting another clinical application although the inhibition of TGF-β may likely exacerbate GVHD.